Latest study leverages new constructs for nuclear localization signal (NLS) sequences to improve editing efficiency in human immune cells.

To obtain high densities of sgRNA that would give signals significantly above the intracellular fluorescent background, especially when the chromatin is in open state during G and S phases ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas ... Here, the authors present dFLASH; a dual FLuorescent transcription factor Activity Sensor for Histone-integrated live-cell reporting for ...

Knocking in genes allows scientists to study the effects of specific gene variants, to use reporter genes like green fluorescent protein to track ... an MD/PhD candidate at the University of ...

In a new development, researchers have successfully created an efficient two-line system for hybrid seed production in ...

When the CRISPR Cas9 protein is added to a cell along with a piece of guide RNA, the Cas9 protein hooks up with the guide RNA and then moves along the strands of DNA until it finds and binds to a ...

Procko grew Venus flytrap plants in tissue culture and then fired gold particles covered with plasmid DNA containing components of the CRISPR-Cas9 system into the cells. In the plasmid, the ...

Various strategies have been developed to enhance the imaging capabilities of CRISPR/Cas9. One approach involves fusing fluorescent proteins to deactivated Cas9 (dCas9), allowing for the ...

Among his recent work at Drexel is the development of technologies based on the CRISPR-Cas9 system for genome mapping and sequencing, which have broad applications in molecular diagnostics, cell/gene ...

Cas9, scientists reconstitute live African swine fever virus from synthetic genomes, accelerating vaccine development for ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.

The company’s CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs ...